Peak serum concentrations (above basal values) were reached within 3 to 6 hours following oral administration of single doses of 0.25 to 1.0 mcg of Rocaltrol (calcitriol) . A study of perinatal and postnatal development in rats resulted in hypercalcemia in the offspring of dams given Rocaltrol at doses of 0.08 or 0.3 mcg/kg/day (approximately 1 and 3 times the maximum recommended dose based on mg/mCalcitriol from ingested Rocaltrol may be excreted in human milk. If serum calcium levels have returned to normal, Rocaltrol therapy may be reinstituted at a dosage of 0.25 mcg/day if previous therapy was at a dosage of 0.5 mcg/day. of Rocaltrol (calcitriol) to patients in excess of their daily requirements can cause hypercalcemia, Rocaltrol is available as capsules containing 0.25 mcg or 0.5 mcg calcitriol and as an oral solution containing 1 mcg/mL of calcitriol. However, many people have no side effects or only have minor side effects. While this is desirable in patients with Magnesium-containing preparations (eg, antacids) and Rocaltrol (calcitriol) should not be used concomitantly in patients on chronic renal dialysis because such use may lead to the development of Studies in dogs and rats given calcitriol for up to 26 weeks have shown that small increases of calcitriol above Excessive dosage of Rocaltrol (calcitriol) induces hypercalcemia and in some instances hypercalciuria; However, A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.Since Rocaltrol also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.Since calcitriol is the most potent active metabolite of vitamin DUncontrolled intake of additional calcium-containing preparations should be avoided  Magnesium-containing preparations (e.g., antacids) may cause hypermagnesemia and should therefore not be taken during therapy with Rocaltrol by patients on chronic renal dialysis.Long-term studies in animals have not been conducted to evaluate the carcinogenic potential of Rocaltrol. Rocaltrol is available as capsules containing 0.25 mcg or 0.5 mcg calcitriol and … A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism.Rocaltrol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. Serial serum electrolyte determinations (especially calcium), rate of urinary calcium excretion, and assessment of electrocardiographic abnormalities due to hypercalcemia should be obtained. Some reports have shown that the concomitant administration of thiazides with Rocaltrol causes hypercalcemia. Calcitriol is a man-made active form of vitamin D. Most people get enough vitamin D from exposure to the sun and from fortified food products (e.g., dairy products, vitamins). with nephrotic The patient and his or her caregivers should be informed about compliance with in the skin to The kidneys of uremic patients cannot adequately synthesize calcitriol, the active The beneficial effect of Rocaltrol (calcitriol) in Calcitriol is rapidly absorbed from the intestine. It has a calculated molecular weight of 416.65 and is soluble in organic solvents but relatively insoluble in water. Man's natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin D 3 (cholecalciferol). Peak serum levels in patients with nephrotic syndrome were reached in 4 hours. Calcitriol is a white, crystalline compound which occurs naturally in humans. During the dosage titration period, serum calcium levels should be obtained Calcium supplements should also be reduced or discontinued.

Samples for serum calcium estimation should be taken without a tourniquet.The recommended initial dose of Rocaltrol (calcitriol) is 0.25 mcg/day. If serum PTH is normal, discontinue Rocaltrol (calcitriol) therapy and monitor patient in 3 months' time.

Calcitriol 0.25 MCG. We anticipate reposting the images once we are able identify and filter out images that do not match the information provided in the drug labels. Calcitriol is the most active known form of vitamin DThe kidneys of uremic patients cannot adequately synthesize calcitriol, the active hormone formed from precursor vitamin D.  Resultant hypocalcemia and secondary hyperparathyroidism are a major cause of the metabolic bone disease of renal failure. In dialysis patients, a fall in serum Should hypercalcemia develop, treatment with Rocaltrol (calcitriol) should be stopped immediately.

Rocaltrol therapy should always be started at the lowest possible dose and should not be increased without careful monitoring of the serum calcium. ROCALTROL® (calcitriol) Capsules And Oral Solution. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters.